Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.43 USD

140.43
1,106,202

-2.57 (-1.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $140.34 -0.09 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MASI) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2

by Zacks Equity Research

HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.

Zacks Equity Research

HealthEquity Acquires WageWorks, To Make Notable Investments

by Zacks Equity Research

HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.

Zacks Equity Research

Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.

Zacks Equity Research

Varian's ProBeam Compact System Picked by University of Miami

by Zacks Equity Research

Varian (VAR) sees notable developments in its Proton Solutions business of late.

Zacks Equity Research

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

DexCom (DXCM) has various favorable factors to maintain the current high.

Zacks Equity Research

Has Masimo (MASI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MASI) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MASI) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.

Zacks Equity Research

Masimo (MASI) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 4.11% and 3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

by Zacks Equity Research

Solid growth in emerging markets is expected to be an added positive this earnings season.

Zacks Equity Research

Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Masimo's (MASI) recent developments likely to show on second-quarter results.

Zacks Equity Research

Masimo (MASI) Q2 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Zacks Equity Research

Here's Why You Should Buy Masimo (MASI) Stock Right Now

by Zacks Equity Research

Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.

Urmimala Biswas headshot

Near-Term Outlook for Medical Instruments Industry Bleak

by Urmimala Biswas

Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

Zacks Equity Research

DaVita Divests DMG to Optum, Boosts Kidney Care Services

by Zacks Equity Research

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

Zacks Equity Research

Here's Why You Should Hold PerkinElmer (PKI) Stock for Now

by Zacks Equity Research

PerkinElmer (PKI) raises earnings per share guidance for 2019.

Zacks Equity Research

Merit Medical Acquires Brightwater Medical for $35 Million

by Zacks Equity Research

The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.

Zacks Equity Research

Here's Why You Should Hold Baxter International (BAX) for Now

by Zacks Equity Research

Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.

Zacks Equity Research

Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment

by Zacks Equity Research

Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.

Zacks Equity Research

Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.

Zacks Equity Research

Varian Medical Buys Endocare & Alicon to Boost Cancer Care

by Zacks Equity Research

Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.